HOTCHKIS & WILEY's HALO Position Overview
HOTCHKIS & WILEY (via Hotchkis & Wiley Capital Management LLC) currently holds 134,630 shares of Halozyme Therapeutics, Inc. (HALO) worth $9.87 M, representing 0.03% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, HOTCHKIS & WILEY has initiated a new position in HALO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
HOTCHKIS & WILEY's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by HOTCHKIS & WILEY
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +134,630 | New Buy | 134,630 | $73.34 |
HOTCHKIS & WILEY's Halozyme Therapeutics Investment FAQs
HOTCHKIS & WILEY first purchased Halozyme Therapeutics, Inc. (HALO) in Q3 2025, acquiring 134,630 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
HOTCHKIS & WILEY has held Halozyme Therapeutics, Inc. (HALO) for 1 quarters since Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
HOTCHKIS & WILEY's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2025, adding 134,630 shares worth $9.87 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, HOTCHKIS & WILEY's firm, Hotchkis & Wiley Capital Management LLC, owns 134,630 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $9.87 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.03% of HOTCHKIS & WILEY's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
HOTCHKIS & WILEY's peak holding in Halozyme Therapeutics, Inc. (HALO) was 134,630 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.